505(j) = ANDA, 505(b)(2) NDA = ‘hybrid’ [Design Issues]

posted by Brus – Spain, 2021-01-25 17:56 (676 d 05:37 ago) – Posting: # 22188
Views: 1,116

Hi Helmut,

❝ So far so good. Since you are mentioning RLD you are targeting the FDA, right?


I called reference product as RLD, but it is not for FDA, it is for EMA. Sorry for the misunderstanding


❝ Is a single (not daily) 150 mg dose approved?


Yes. According SmPC of reference product, it is possible to administer one single dose of 150 mg.

❝ In Europe that’s the hybrid pathway. Additionally to this study generally clinical studies are required as well.


Why? If efficacy has indeed been demonstrated with 150 mg and SmPC establishes a 150 mg dose regimen. What more can you ask for? To my understanding, you just have to show that your 150 mg provided in your tablet will behave in the same way as the 150 mg of the reference product provided by a 100 mg tablet and a 50 mg tablet. What am I missing?

Best regards,

Complete thread:

UA Flag
Activity
 Admin contact
22,424 posts in 4,694 threads, 1,600 registered users;
13 visitors (1 registered, 12 guests [including 7 identified bots]).
Forum time: 23:33 CET (Europe/Vienna)

The rise of biometry in this 20th century,
like that of geometry in the 3rd century before Christ,
seems to mark out one of the great ages or critical periods
in the advance of the human understanding.    R.A. Fisher

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5